Hemoglobinopathy Market (By Type: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb Variants Diseases; By Therapy: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb Variants Diseases; By Diagnosis: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb variants diseases) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

According to Acumen Research and Consulting, the global Hemoglobinopathy market is expected to grow at noteworthy CAGR around 10 % throughout the forecast period and reach around US$ 12 billion by 2026.

Hemoglobinopathy is a genetic disorder that causes structural abnormalities in hemoglobin molecules. Hemoglobinopathies are hereditary single-gene diseases which are the most common type of Sickle Cell disease. In Africa, South East Asia and the Mediterranean basin, hemoglobinopathies are highly prevalent. Critical cases of hemoglobinopathy lead to anemia, dysfunction of the organ or death if left untreated. The diagnostic tests for the presence of hemoglobinopathies involve Gel electrophoresis and complete blood count. The disease has no permanent cure ; this has led to an increased demand in the pharmaceutical sector for new product innovations. The high prevalence of disease and the national control programme, in developing economies, also drive the need for drug therapy.

The report provides analysis of global Hemoglobinopathy market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Dynamics

Increasing cases of hemoglobinopathy are one of the major driving forces for growth, especially in regions such as Southeast Asia and Africa. Roughly 300,000 to 500,000 children born every year have hemoglobin disorders as per the World Health Organization (wHO). According to them. More than half of children born with Hb disorders suffer from sickle cell disease (SCD) and thalassemia. Failure to become aware of these diseases increases the death to survival ratio for SCD and thalassemia patients. The National Institutes of Health is expected to promote market growth over the predictive period by increasing government and enterprise awareness-raising initiatives for hemoglobin variants such as the launch of the Sickle Cell Initiative in September 2018.

Usual neonatal screening programs are effective measures to help detect potentially harmful and fatal problems, such as thalassemia and SCD, at an early stage in children, in particular in advanced countries. The CDC and the Association of the Laboratories for Public Health partnered for hemoglobinopathy for the newborn health screening programme, for example, in 2013, in the Division of Blood Disorders. This project was launched to support laboratories to evaluate complications associated with hemoglobinopathies and also provide caregivers, health care workers and patients with education on hemoglobinopathy screening programs.

Another reason for the growth of the market is the increase in R&D activities aimed at developing new therapeutics. The NHLBI supports SCD research programs to develop new ways to detect, treat and improve the condition and the outcomes of patients and the National Heart, Lung, and Blood Institute (NHLBI). New methods, which include replacing or editing the faulty SCD gene as well as transplanting the corrected gene back to the patient, are being developed with progress in gene-editing technology. Increased SCD prevention and treatments grants are also expected to contribute to improved disease management by enacting the laws of the Sickle Cell Disease Research, Surveillance, Prevention and the Treatment Act in 2018.

Type Outlook

Thalassemia (beta and alpha), sickle cell diseases and other hemoglobinopathies, such as hereditary elliptocytosis, are the market segments. Globin gene mutations create a variety of hereditary conditions that lead to blood disorders such as thalassemia and SCD.

As regards sales in 2018, SCD was the largest segment. Due to the increasing effort to increase patient awareness of the disease and further improvements in diagnosis and treatment, the segment is also projected to expand over the forecast period at a healthy CAGR.

Diagnostic Stance

The diagnosis segment was led by blood testing in 2018 with revenue. It is a major contributor to its main market share that blood testing is commonly used as the first line screening method. Due to its efficiency in accurate diagnosis and monitoring, genetic testing for SCD is expected to become a fastest growing segment over the forecast period. Pre implantation The most rapidly growing segment of genetic diagnosis (PGD) is expected to be thalassemia because of the advantages of the technique of diagnosis, such as in-vitro (IVF) genetic monitors.

Therapy Outlook

Based on therapy, blood transfusion, iron chelatory treatment, bone marrow transplantation and others are the categories of the market. The largest market share in 2018 was in blood transfusion therapy. Increased government initiatives to increase blood donation have a major impact on the hemoglobinopathy market.

The most important requirement is permanent cure for hemoglobinopathy. In the near future, promising pipeline drugs maintained on accelerated review will meet the market needs. In July 2018, for example, the accelerated evaluation by the Committee for Human Drug Products for the European Medicines Agency (CHMP) of bluebird organothérapy, LentiGlobin, indicated for use in the treatment of sickle cell disease, was granted.

Regional Stance

Due to the increasing investment in R&D from major players, better reimbursement scenario and high quality sanitary infrastructure, North America led the overall revenue market in2018.

During the forecast period, Asia Pacific is expected to be experiencing fastest growth. It is expected, in future, that producers will have lucrative growth opportunities with the establishment of indigenous, low-cost diagnostic kits for thalassemia and Sicle-cell disease, coupled with an increasing patient awareness.

Although hemoglobinopathy incidence is large throughout underdeveloped economies, including nations in South-East Asia and the Subsaharan area, a stronger system of healthcare is anticipated to enhance worldwide hemoglobinopathies in the advanced markets and advanced economies in North America and Asia-Pacific respectively. Advanced diagnostics and therapeutics are probable to increase business development in the next few years.

Market Segmentation

Global Hemoglobinopathy Market, By Type

• Thalassemia
  
  • Beta Thalassemia
  • Alpha Thalassemia
• Sickle Cell Disease
• Other Hb Variants Diseases

Global Hemoglobinopathy Market, By Therapy

• Thalassemia
  
  • Beta Thalassemia
  • Alpha Thalassemia
• Sickle Cell Disease
• Other Hb Variants Diseases

Global Hemoglobinopathy Market, By Diagnosis

• Thalassemia
  
  • Beta Thalassemia
  • Alpha Thalassemia
• Sickle Cell Disease
• Other Hb variants diseases

Global Hemoglobinopathy Market, By Geography

• North America.
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

The market research study on “Hemoglobinopathy Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Hemoglobinopathy market segments with market dynamics and their impact. The report also covers basic technology development policies.

The report provides an analysis of the latest industry trends from 2015 to 2026 in all sub-segment segments and forecasts revenue and volume growth on the global, the regional and country levels.

Key Players & Strategies

With the presence of regional and local players, the world Hemoglobinopathy market is fragmented. The market has been acquired by major companies by key manufacturers. Alnylam Pharmaceuticals; Gamida Cell; Global Blood Therapeutics Inc.; bluebird media Inc.; Emmaus Life Sciences Inc.; Sanofi: Prolong Pharmaciens; and Celgene Corporation are the main business competitors.

Key competitors focus on cooperation and licensing agreements for the exchange of technical knowledge linked to therapeutic haemoglobinopathy. For example, in January 2014, the global cooperation agreement for therapeutic development of hemoglobinopathy was announced by Bioverativ and Sangamo Therapeutics, Inc.